Pages

▼
Showing posts with label out-licensing. Show all posts
Showing posts with label out-licensing. Show all posts
Friday, October 18, 2013

Deals Of The Week: Academic Drug-Discovery Alliance Capturing Industry's Notice

›
Nashville hosted the first annual conference of the Academic Drug Discovery Consortium It’s become a familiar story in biopharma, as...
Friday, August 02, 2013

Deals Of The Week: A Feeding Frenzy Over ROR Gamma T Modulators?

›
A little-heralded deal between Amgen and Japan’s Teijin Pharma  July 31 marked the sixth since 2009 around compounds that modulate the ROR...
Monday, December 10, 2012

M&A Deal of the Year Nominee: Biogen/Stromedix

›
It's time for the IN VIVO Blog's Fifth Annual Deal of the Year! competition. This year we're once again presenting awards in th...

Alliance Deal of the Year Nominee: Tolero/Mannkind

›
It's time for the IN VIVO Blog's Fifth Annual Deal of the Year! competition. This year we're once again presenting awards in th...
Friday, May 04, 2012

Deals Of The Week: Tolero Introduces Itself In "Double-Jointed" Deal With MannKind

›
In a deal structure that perhaps could best be described as “double-jointed,” new company Tolero Pharmaceuticals has licensed exclusive ...
Wednesday, December 07, 2011

2011 Alliance of the Year Nominee: Pfizer/Puma

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...
Friday, October 15, 2010

Deals of the Week Has Playoff Fever and Poison Ivy

›
Deals of the Week! doesn't usually get up on our soapbox and complain unless it's to gripe about undisclosed deal terms, vaguely wor...
Thursday, February 25, 2010

Merck Puts Up Its Asset-Sale Shingle

›
Big Pharma has been slow to adopt out-licensing strategies for a plethora of reasons: fear it will regret giving up something that could tur...